- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07610070
Comparative Study Between Ultrasound Guided Paravertebral Plane Block and Erector Spinae Plane Block on Post-operative Analgesia After Total Abdominal Hysterectomy
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The intent of this study is to compare the efficacy of the erector spinae plane block (ESPB) and paravertebral plane block in reducing postoperative opioid consumption and pain in patients with total abdominal hysterectomy. All patients will be assessed preoperatively by history taking, full physical examination, and laboratory evaluation CBC, coagulation, kidney and liver function. inform the patient about VAS score, On arrival of the patients to the operating room, electrocardiography, non-invasive blood pressure, and pulse oximetry will be applied. the vital signs parameters including mean arterial pressure (MAP), heart rate (HR), respiratory (RR) and SpO2 will be measured every 5 minutes recorded at base line and every 30 minutes till end of surgery. Intravenous (IV) line will be inserted and IV fluids 500ml normal saline will be started.
In the induction of general anesthesia, the patient will receive intravenous fentanyl (2 μg /kg) and propofol (2 mg/kg). atracurium (0.5 mg/kg) then tracheal intubation and the mechanical ventilator will be employed to maintain the end-tidal CO2 between 30 and 35 mmHg. Depending on the requirements of the patient, both inhaled (Sevoflurane) and intravenous (IV) atracurium will be utilized for anesthetic maintenance.
Preparation of local anesthesia 20 ml bupivacaine 0.25% for the block for each side without exceeding the toxic dose 2mg/kg [. then the block will be performed on the lateral position.
Both blocks will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath.
Group 1(Paravertebral Plane Block) (24 Patients); The spinous process of the 10th thoracic vertebra will be located under the ultrasound guided (USG) linear probe. Under aseptic precautions, a 22-G short-beveled needle will be inserted under ultrasonographic guidance using the in-plane approach and was directed medially between the transverse process (TP) and the pleura. The needle will traverse the superior costotransverse ligament and enter the paravertebral space, where 2 ml of normal saline will be injected. The tip of the needle will be in the paravertebral space, noting the pleura being pushed down. Then, 20 ml of 0.25% bupivacaine will be injected into the paravertebral space under USG visualization.
Group 2 (Erector Spinae Plane Block) (24 Patients); The USG linear probe will be placed Longitudinal 3 cm lateral to T10 transverse process TP. A 22-G short-beveled needle will be inserted in the cephalad to caudal direction through the erector spinae to contact the T10 TP using the in-plane technique. After the needle made contact with TP, the plane will be confirmed by injecting 2ml of saline and depositing 20ml of 0.25% bupivacaine.
Monitor HR & MAP and if any increase more than 20% from the baseline value will receive fentanyl 50 µg IV incremental and recording total dose of fentanyl consumption
All patients receive:
Dexamethasone 8 mg IV and Ondansetron 4 mg IV
Reversal:
Neostigmine 0.05 mg/kg and Atropine 0.02 mg/kg Post-operative settings: At the end of the surgery, the patient will be kept under observation postoperatively in the recovery room for 30 min to monitor vital signs (mean arterial pressure, heart rate, respiratory rate) and the conscious level then will be discharged to the ward to be followed.
Postoperative pain: The assessment of postoperative pain will be evaluated postoperatively in the recovery room on arrival (zero time), after 30 minutes, 2,4,6,8,12,16,20, and 24 hours postoperatively in the surgical ward with visual analogue scale (1-10).
All patients will receive paracetamol 1 gm every 8 hrs. At score of3 or more, rescue analgesic 3 mg morphine iv Will be given. Total analgesic dose of morphine during first 24 hours will be recorded.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Doaa Ramadan, MBBCH
- Telefoonnummer: 01145211869
- E-mail: DoaaRamadan@med.asu.edu.eg
Studie Contact Back-up
- Naam: Doaa Ramadan, MBBCH
- Telefoonnummer: 01145211869
- E-mail: doaaramdan2020@gmail.com
Studie Locaties
-
-
Abbasia
-
Cairo, Abbasia, Egypte, 00202
- Ain Shams
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- ASA I and ASA II patients.
- Female, 30-60 years of age.
- Scheduled for total abdominal hysterectomy.
Exclusion criteria:
- Patient refusal of procedure or participation in the study.
- Opioid or analgesic abuse.
- Known allergy to study drug.
- Any contraindication of regional anesthesia including:
- Local infection at the site of puncture.
- Having history of hematological disorders, including coagulation abnormality.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Paravertebral Plane Block
the group will receive paravertebral plane block, The spinous process of the 10th thoracic vertebra will be located under the ultrasound guided (USG) linear probe.
Under aseptic precautions, a 22-G short-beveled needle will be inserted under ultrasonographic guidance using the in-plane approach and was directed medially between the transverse process (TP) and the pleura.
The needle will traverse the superior costotransverse ligament and enter the paravertebral space, where 2 ml of normal saline will be injected.
The tip of the needle will be in the paravertebral space, noting the pleura being pushed down.
Then, 20 ml of 0.25% bupivacaine will be injected into the paravertebral space under USG visualization.
|
The spinous process of the 10th thoracic vertebra will be located under the ultrasound guided (USG) linear probe.
Under aseptic precautions, a 22-G short-beveled needle will be inserted under ultrasonographic guidance using the in-plane approach and was directed medially between the transverse process (TP) and the pleura.
The needle will traverse the superior costotransverse ligament and enter the paravertebral space, where 2 ml of normal saline will be injected.
The tip of the needle will be in the paravertebral space, noting the pleura being pushed down.
Then, 20 ml of 0.25% bupivacaine will be injected into the paravertebral space under USG visualization.
20 ml of 0.25% bupivacaine will be injected
|
|
Actieve vergelijker: Erector Spinea Plane Block
the group will receive Erector Spinae Plane Block; The USG linear probe will be placed Longitudinal 3 cm lateral to T10 transverse process TP.
A 22-G short-beveled needle will be inserted in the cephalad to caudal direction through the erector spinae to contact the T10 TP using the in-plane technique.
After the needle made contact with TP, the plane will be confirmed by injecting 2ml of saline and depositing 20ml of 0.25% bupivacaine.
|
20 ml of 0.25% bupivacaine will be injected
The USG linear probe will be placed Longitudinal 3 cm lateral to T10 transverse process TP.
A 22-G short-beveled needle will be inserted in the cephalad to caudal direction through the erector spinae to contact the T10 TP using the in-plane technique.
After the needle made contact with TP, the plane will be confirmed by injecting 2ml of saline and depositing 20ml of 0.25% bupivacaine.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
total morphine consumption
Tijdsspanne: from the end of surgey to 24 hrs post operative
|
Postoperative total morphine requirements in the first 24 hours after surgery.
|
from the end of surgey to 24 hrs post operative
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- FMASU MD354/2025
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .